Marshall Wace North America’s VYNE Therapeutics VYNE Stock Holding History

Marshall Wace North America’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,172	Closed	-$1.25M	–	1814
2021 Q1	$1.25M	Buy	+10,172	New	+$1.47M	0.01%	967
2019 Q1	–	Sell	-269	Closed	-$80K	–	1931
2018 Q4	$80K	Buy	+269	New	+$120K	﹤0.01%	1131
2018 Q2	–	Sell	-436	Closed	-$1.18M	–	1717
2018 Q1	$1.18M	Buy	+436	New	+$1.06M	0.01%	949

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Marshall Wace North America's VYNE Position: Q2 2021 in Review

Marshall Wace North America sold out of VYNE Therapeutics (VYNE) in Q2 2021, closing a stake of 10,172 shares — an estimated $1.25M sold.

Marshall Wace North America first reported a position in VYNE in Q1 2018 and held it in 3 quarters. The position peaked at $1.25M in Q1 2021. 72 funds tracked by Wall St. Rank hold VYNE as of Q2 2021.

Marshall Wace North America reported no remaining VYNE Therapeutics position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 10,172 VYNE Therapeutics shares in Q2 2021, an estimated $1.25M.
Marshall Wace North America first reported a position in VYNE Therapeutics in Q1 2018 and held it in 3 quarters.
Marshall Wace North America's VYNE Therapeutics position peaked at $1.25M in Q1 2021.
72 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.